Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Voruciclib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 known ✓ | P11802 | 14/20 | 1.00 |
| ▸ | CDK2 | P24941 | 13/20 | 1.00 |
| ▸ | CDK9 | P50750 | 13/20 | 1.00 |
| ▸ | CDK1 | P06493 | 13/20 | 1.00 |
| ▸ | CCND1 | P24385 | 12/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 11/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 10/20 | 1.00 |
| ▸ | CDK6 | Q00534 | 5/20 | 1.00 |
| ▸ | CDK8 | P49336 | 4/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 4/20 | 1.00 |
| ▸ | CCNT2 | O60583 | 1/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.82 |
| ▸ | CCND3 | P30281 | 4/20 | 0.82 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.82 |
| ▸ | CCNC | P24863 | 1/20 | 0.82 |
| ▸ | CCNB2 | O95067 | 6/20 | 0.76 |
| ▸ | CCNB3 | Q8WWL7 | 6/20 | 0.76 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.76 |
| ▸ | GSK3A | P49840 | 4/20 | 0.76 |
| ▸ | CDK7 | P50613 | 3/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Voruciclib SCHEMBL30337774 | 1.00 | CDK4 (1.00) | CDK4CDK2CDK9CDK1CCND1 | |
| Voruciclib SCHEMBL29788352 | 1.00 | CDK4 (1.00) | CDK4CDK2CDK9CDK1CCND1 | |
| Voruciclib SCHEMBL30338136 | 1.00 | CDK4 (1.00) | CDK4CDK2CDK9CDK1CCND1 | |
| Voruciclib SCHEMBL3108205 | 1.00 | CDK4 (1.00) | CDK4CDK2CDK9CDK1CCND1 | |
| Voruciclib SCHEMBL29366894 | 1.00 | CDK4 (1.00) | CDK4CDK2CDK9CDK1CCND1 | |
| Voruciclib SCHEMBL23436512 | 1.00 | CDK4 (1.00) | CDK4CDK2CDK9CDK1CCND1 | |
| Voruciclib SCHEMBL2446324 | 1.00 | CDK4 (1.00) | CDK4CDK2CDK9CDK1CCND1 | |
| Voruciclib SCHEMBL2441383 | 0.99 | CDK4 (0.98) | CDK4CDK2CDK9CDK1CCND1 | |
| Voruciclib SCHEMBL2441390 | 0.99 | CDK4 (0.98) | CDK4CDK2CDK9CDK1CCND1 | |
| Voruciclib SCHEMBL2441386 | 0.99 | CDK4 (0.98) | CDK4CDK2CDK9CDK1CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383529-B2 | Pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2025-08-12 | — | — | US | claimed |
| US-20240390325-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | Piramal Enterprises Limited (IN) | 2024-11-28 | — | — | US | claimed |
| US-11925618-B2 | Pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2024-03-12 | — | — | US | claimed |
| US-11234963-B2 | Pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2022-02-01 | — | — | US | claimed |
| US-10555931-B2 | Pharmaceutical combination for the treatment of cancer | Piramal Enterprises Limited (IN) | 2020-02-11 | — | — | US | claimed |
| EP-2714031-B1 | A SYNERGISTIC PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF SQUAMOUS CELL CARCINOMA OF HEAD AND NECK | PIRAMAL ENTPR LTD (IN) | 2018-05-23 | — | — | EP | claimed |
| EP-2046738-B1 | ENANTIOMERICALLY PURE FLAVONE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AND PROCESSES FOR THEIR PREPARATION | PIRAMAL ENTPR LTD (IN) | 2014-06-11 | — | — | EP | claimed |
| US-8563596-B2 | Enantiomerically pure compounds for the treatment of proliferative disorders | Piramal Enterprises Limited (IN) | 2013-10-22 | — | — | US | claimed |
| US-20100179210-A1 | NOVEL ENANTIOMERICALLY PURE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Piramal Enterprises Limited (IN) | 2010-07-15 | — | — | US | claimed |
| EP-2046738-A1 | ENANTIOMERICALLY PURE FLAVONE DERIVATIVES FOR THE TREATMENT OF POLIFERATIVE DISORDERS AND PROCESSES FOR THEIR PREPARATION | Piramal Life Sciences Limited (IN) | 2009-04-15 | — | — | EP | claimed |
| WO-2007148158-A1 | ENANTIOMERICALLY PURE FLAVONE DERIVATIVES FOR THE TREATMENT OF POLIFERATIVE DISORDERS AND PROCESSES FOR THEIR PREPARATION | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2007-12-27 | — | — | WO | claimed |
| US-20260069567-A1 | Pharmaceutical Combinations For The Treatment Of Cancer | PRESAGE BIOSCIENCES, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-12421216-B2 | Voruciclib polymorphs and methods of making and using thereof | MEI PHARMA, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12383530-B2 | Pharmaceutical combination for the treatment of melanoma | Piramal Enterprises Limited (IN) | 2025-08-12 | — | — | US | disclosed |
| US-20250221961-A1 | Pharmaceutical Combinations For The Treatment Of Cancer | PRESAGE BIOSCIENCES, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| US-20120316216-A1 | PYRROLIDINE SUBSTITUTE FLAVONES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Piramal Enterprises Limited (IN) | 2012-12-13 | — | — | US | disclosed |
| WO-2011104584-A1 | PYRROLIDINE SUBSTITUTED FLAVONES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-09-01 | — | — | WO | disclosed |
| US-20100179210-A1 | NOVEL ENANTIOMERICALLY PURE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Piramal Enterprises Limited (IN) | 2010-07-15 | — | — | US | disclosed |
| EP-2046738-A1 | ENANTIOMERICALLY PURE FLAVONE DERIVATIVES FOR THE TREATMENT OF POLIFERATIVE DISORDERS AND PROCESSES FOR THEIR PREPARATION | Piramal Life Sciences Limited (IN) | 2009-04-15 | — | — | EP | disclosed |
| WO-2007148158-A1 | ENANTIOMERICALLY PURE FLAVONE DERIVATIVES FOR THE TREATMENT OF POLIFERATIVE DISORDERS AND PROCESSES FOR THEIR PREPARATION | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383530-B2 | Pharmaceutical combination for the treatment of melanoma | BRAF, CCNI, CDK1 | CDK4 4/4885CDK2 10/4885CDK9 8/4885 |
| US-12421216-B2 | Voruciclib polymorphs and methods of making and using thereof | PRKACB, PRKACA, PRKDC | CDK4 493/4885CDK2 177/4885CDK9 161/4885 |
| US-20100179210-A1 | NOVEL ENANTIOMERICALLY PURE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CDK2, CDK9, CDK1 | CDK4 5/4885CDK2 1/4885CDK9 2/4885 |
| US-20250221961-A1 | Pharmaceutical Combinations For The Treatment Of Cancer | CDKL2, BCL9, CDK6 | CDK4 11/4885CDK2 44/4885CDK9 19/4885 |
| US-20120316216-A1 | PYRROLIDINE SUBSTITUTE FLAVONES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, SYVN1, PAH | CDK4 1833/4885CDK2 1402/4885CDK9 2540/4885 |
| US-20260069567-A1 | Pharmaceutical Combinations For The Treatment Of Cancer | BCL6, BCL6B, BCL9 | CDK4 10/4885CDK2 28/4885CDK9 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.